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Autologous fibroblasts therapy for recessive dystrophic epidermolysis bullosa
J Jackow, M Titeux, S Charbonnier and A Hovnanian Inserm UMR 1163 and Imagine Institute 
of Genetic Diseases, Paris, France
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe genetic skin fragility disorder caused 
by mutations in the COL7A1 gene encoding type VII collagen, which is the major constituent of 
anchoring fibrils (AF) at the basement membrane zone (BMZ). Patients with RDEB lack type VII 
collagen and therefore have severely impaired dermal-epidermal stability. There is currently no 
specific treatment for RDEB and several approaches using gene, cell and protein-based strategies 
are being developed. In addition to gene addition, we are developing a cell-based therapy based 
on the injection of autologous genetically corrected RDEB fibroblasts. We used a GMP-certified 
batch of self-inactivating (SIN) retrovirus-based vector to restore type VII collagen expression in 
primary RDEB patient fibroblasts. Transduction efficiency was 50 % and led to abundant expression 
of type VII collagen mRNA and protein. Furthermore, restoration of type VII collagen expression 
significantly improved RDEB fibroblast adhesion in vitro. To test the potential of this approach in 
vivo, genetically corrected patient fibroblasts were injected into reconstructed human RDEB skin 
equivalent transplanted onto immune-deficient mice. Three million cells were subcutaneously 
injected into the back skin of mice under the transplanted RDEB skin equivalent. Two months after 
treatment, the reconstructed patient skin equivalents showed restored expression of human type VII 
collagen and the presence of AF with a typical loop-shape structure at the BM zone. Taken together, 
these pre-clinical results provide evidence that the injection of human RDEB fibroblasts genetically 
corrected with a SIN-COL7A1 retroviral vector has the capacity to restore normal type VII collagen 
deposition at the BM zone and AF formation in RDEB reconstructed skin. Clinical translation of this 
protocol using GMP-certified genetically corrected autologous RDEB fibroblasts has a potential for 
future treatment of localised wounds in RDEB patients.    
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Steady state pharmacokinetics, tolerability and safety of XP23829, a novel fumaric acid ester 
(FAE) for the treatment of moderate-to-severe plaque psoriasis
AB Gottlieb,1 R Kim,2 LN Clark2 and D Lissin2 1 Dermatology, Tufts Medical Center, Boston, 
MA and 2 XenoPort, Inc., Santa Clara, CA
The objective is to assess the pharmacokinetics (PK), tolerability, and safety of an extended release 
(ER) FAE formulation after repeated daily dosing. XP23829 is a prodrug of monomethyl fumarate 
(MMF), the active metabolite produced by dimethyl fumarate (DMF). DMF is currently licensed in 
Germany for the treatment of moderate-to-severe psoriasis vulgaris and in the US for relapsing forms 
of multiple sclerosis. XP23829 ER has the potential for providing sustained plasma levels of MMF, 
reducing dosing frequency, and improving tolerability. The study is a randomized, double-blind, 
placebo-controlled, oral-dose PK study with healthy adults in sequential cohorts of 12 active and 3 
placebo. Each cohort received 7 days of XP23829 at target dose after titration: at 800 mg QD and at 
500 mg BID. The PK of MMF was determined on Day 7. Safety was evaluated by monitoring adverse 
events (AEs), laboratory testing, and ECGs. Clinical labs were assessed at screening, baseline, Day 8 
(1 day after last dose) and follow-up (8-10 days after last dose). Mean maximum steady-state MMF 
concentrations (Cmax,ss) in plasma for XP23829 were 1830 and 1170 ng/mL at 800 mg QD (fed) 
and 500 mg BID (fed), respectively; the mean area under the curve (AUC24,ss) was 5080 and 5510 
ng*hr/mL. The half-life of MMF was 1.4 to 1.9 hr for XP23829. No serious AEs were reported in 
doses of XP23829 up to 1000 mg daily. The vast majority of AEs were mild to moderate in intensity. 
Flushing and GI effects were the most frequently reported AEs, consistent with the safety profile of 
DMF. Similar to effects described for DMF, XP23829 reduced blood lymphocytes. Lymphocytes 
did not drop below 0.5 x 109 /L in any subject and returned to near baseline levels at follow-up. 
In conclusion, XP23829 is safe, well-tolerated and provides sustained MMF exposure, with PK 
supporting potential once-a-day dosing. XP23829 is currently undergoing evaluation in a phase 2, 
dose-finding study in moderate-to-severe plaque psoriasis.    
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Pentobra: A novel antimicrobial compound with lytic activity against Propionibacterium 
acnes
GW Agak,1 NW Schmidt,2 S Deshayes2, 3, Y Yu,1 A Blacker2, 3, J Champer,1 W Xian2, 3, 
S Kao,1 A Kasko2, 4, GC Wong2, 3, 4 and J Kim1, 4, 5 1 Medicine, David Geffen School of 
Medicine at UCLA, Los Angeles, CA, 2 Bioengineering, Department of Bioengineering, UCLA, 
Los Angeles, CA, 3 Department of Chemistry and Biochemistry, UCLA, Los Angeles, CA, 4 
California Nanosystems Institute, University of California, Los Angeles, CA and 5 Department 
of Dermatology, Greater Los Angeles Healthcare System Veterans Affairs, Los Angeles, CA
 Propionibacterium acnes resistance to antibiotics is an increasing problem. To address this chal-
lenge, we engineered a novel P. acnes antibiotic by combining the potent ribosomal activity of 
aminoglycosides with the membrane-permeabilizing abilities of antimicrobial peptides (AMP). Our 
design is informed by rules which relate cationic and hydrophobic properties of AMP sequences, 
cell–penetrating peptide sequences, and non-peptidic AMP mimetic compositions, to the geometric 
requirements of membrane permeabilization. Tobramycin, a potent aminoglycoside, is conjugated 
to a short 12 amino acid peptide to equip the composite molecule, Pentobra, with membrane-per-
meabilizing activity. Pentobra demonstrated potent and selective killing of P. acnes and drastically 
outperformed free tobramycin (by 5-7 logs) against multiple P. acnes strains. Moreover, EM studies 
showed that Pentobra also had robust membrane activity, as treatment with Pentobra killed P. acnes 
cells and caused leakage of intracellular contents. In addition, Pentobra may also have potential 
anti-inflammatory effects as demonstrated by suppression of some, but not all, P. acnes-induced 
chemokines. Importantly, the antimicrobial activity was maintained in sebaceous environments 
as Pentobra was bactericidal against P. acnes clinical isolates in comedone extracts isolated from 
human donors. Our study demonstrates that equipping aminoglycosides with an additional mech-
anism of action that targets membrane activity is a viable approach for developing novel antibiotics 
against P. acnes.    
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Hematopoietic cell transplantation (HCT) for recessive dystrophic epidermolysis bullosa 
(RDEB): reduced intensity conditioning (RIC) has a better outcome than myeloablative con-
ditioning (MAC)
J Tolar,1 J McGrath,2 MJ Osborn,1 DR Keene,3 K Hook,6 M Hordinsky,8 DT Woodley,4 
M Chen,4 A Hovnanian,5 K Tamai,7 B Blazar1 and J Wagner1 1 Pediatric Blood and Marrow 
Transplantation, University of MN, Minneapolis, MN, 2 King’s College London, London, 
United Kingdom, 3 Shriners Hospital, Portland, OR, 4 Dermatology, University of Southern 
California, Los Angeles, CA, 5 Necker Hospital, INSERM UMR1163, Paris, France, 6 
Dermatology, University of Minnesota, Minneapolis, MN, 7 Department of Stem Cell Science, 
Osaka, Japan and 8 University of Minnesota, Minneapolis, MN
In RDEB, loss-of-function mutations in COL7A1 gene result in diminished or absent type VII colla-
gen (C7), severe mucocutaneous wounds, mutilating scarring, and predilection for squamous cell 
carcinoma. Between 2007 and 2014, 26 individuals (0.4-20y) with severe generalized RDEB have 
undergone allogeneic HCT at the University of Minnesota. Of these, 13 were treated with MAC 
(busulfan, fludarabine [FLU], and cyclophosphamide [CY]) and 13 were treated with RIC (CY, FLU, 
anti-thymocyte globulin, and low dose total body irradiation). RDEB subjects received HCT from 
HLA-matched related (N=15, all bone marrow grafts), or unrelated donors (N=11; 6 bone marrow 
and 5 cord blood grafts). When compared to MAC, RIC was far better tolerated with a marked 
reduction in the risk of infection and organ toxicity. The overall probability of 2-year survival in the 
MAC cohort was 69% (95% CI, 37-87 %) versus 90% (95% CI, 47-99%) for the RIC cohort (p=0.32). 
For the entire cohort of engrafted, surviving individuals with RDEB thus far (N=18), 14 individuals 
demonstrated partial to marked biochemical and clinical improvement in mucocutaneous disease on 
the basis of C7 expression, body surface area affected, or resistance to blistering. We conclude that 
RIC has a tendency to improve the outcome of patients with severe generalized RDEB undergoing 
allogeneic HCT. Further, HCT has the potential of being a durable, systemic therapy for people with 
different forms and severities of EB, and sets the stage for using hematopoietic cells in the treatment 
of a broad spectrum of extracellular matrix disorders.    
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Novel long-non-coding RNA in melanoma: MIRAT a biomarker of small molecule inhibitor 
response
M Sanlorenzo, I Vujic, C Posch, K Lai, K Lin, D Gho, A Moy, A Gajjala and S Ortiz-Urda 
Dermatology, University of California San Francisco, San Francisco, CA
Oncogenic BRAF and NRAS proteins are found in 70-80% of all melanomas. The mutations lead 
to hyper-active signaling through their downstream cascades, which leads to tumor growth and 
uncontrolled proliferation. FDA-approved BRAF and MEK inhibitors inhibit components of these 
cascades and are currently used in many melanoma patients. In order to explore potential models of 
resistance to these inhibitors, we have used established protocols to develop cell lines with acquired 
resistance to MEK (trametinib) and BRAF (Plx 4720) inhibition. RNA from parental and resistant 
cell lines was sent to RNA-seq. We compared the FPKM (Fragments Per Kilobase per Million reads 
mapped) values and identified a novel transcript that was expressed only in the resistant cell lines. 
We termed the transcript ‘MIRAT’ (MAPK Inhibitor Resistance Associated Transcript). We confirmed 
the presence of MIRAT in BRAF and NRAS mutant resistant cell lines with RNA-FISH probes and 
TaqMan PCR. To see if MIRAT is involved in cell resistance to small molecule inhibitors of the 
MAPK pathway we performed siRNA knockdown experiments. A pool of siRNA directed against 
MIRAT showed a cell viability decrease in our resistant cell lines. Encouraged by these results, 
we tested siRNA against MIRAT in cell lines that showed an innate resistance to trametinib. Also 
here, we could observe a cell viability decrease following siRNA incubation. The knockdown of 
MIRAT led to a decreased protein level of DUSP 6, followed by an induction of pp38, pp53 and 
p21 and a decreased level of pRB in our cells, thus partly explaining the mechanistic of the novel 
transcript. MIRAT was also found in patients’ derived BRAF mutant avatar cell lines resistant to the 
combination of BRAF and MEK inhibitors. MIRAT could serve as potential biomarker of response 
to the inhibitors of the MAPK cascade in melanoma.    
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Drug repurposing for dermatomyositis using public expression datasets
HG Cho,3 DF Fiorentino,1 M Sirota2, 4 and K Sarin1 1 Department of Dermatology, Stanford 
University Medical Center, Stanford, CA, 2 Division of Systems Medicine, Department of 
Pediatrics, Stanford University School of Medicine, Stanford, CA, 3 School of Medicine, 
Stanford University, Stanford, CA and 4 Department of Biomedical Informatics, Stanford 
University School of Medicine, Stanford, CA
Dermatomyositis (DM) is a rare autoimmune disorder characterized by inflammation of the skin and 
muscle. Although the cutaneous manifestations of DM can be debilitating, current therapeutics for 
the skin lesions in DM are limited, reinforcing the need for a systematic approach to discover novel 
therapeutics. Here, we applied a bioinformatics approach combining gene expression data of over 
47,000 transcripts from 48 lesional DM skin biopsies with gene expression data from over 1,400 
U.S. Food and Drug Administration (FDA)-approved drugs to identify potential novel therapeutics 
for the treatment of DM skin. Amongst the top 53 drugs predicted by our bioinformatics approach 
were methotrexate, an antimetabolite, and rituximab, a monoclonal antibody against CD20, both 
of which have been shown to have efficacy in the treatment of DM skin. In addition, the alpha-1 
agonist, oxymetazoline, was identified as a potential novel therapeutic for the skin lesions in DM 
(p < 0.01). To explore this further, oxymetazoline was applied topically to the affected skin of 
two DM patients, one of whom experienced significant improvement in her skin symptoms and 
redness. These findings support further studies on the use of oxymetazoline for the treatment of 
DM skin and demonstrate the potential of bioinformatics-based drug screening to identify novel 
therapeutics for DM.    
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Allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epider-
molysis bullosa: an open-label, phase 1, single-centre trial 
G Petrof,1 SM Lwin,1 M Martinez-Quiepo,1 A Abdul-Wahab,1 S Tso,1 J Mellerio1, 2, I Slapen-
Cortenbach,3 JJ Boelens,3 J Tolar,4 P Veys,2 T Kadiyirire,1 M Ofuya,1 JL Peacock,1 A Martinez2 
and J McGrath1 1 King’s College London, London, United Kingdom, 2 Great Ormond 
Street Hospital, London, United Kingdom, 3 University Medical Centre Utrecht, Utrecht, 
Netherlands and 4 University of Minnesota, Minneapolis, MN
Individuals with recessive dystrophic epidermolysis bullosa (RDEB) have life-long fragile skin and 
chronic wounds. RDEB is caused by bi-allelic mutations in COL7A1, leading to a lack of basement 
membrane type VII collagen (C7). Currently, there is no cure for this condition. We conducted an 
open-label, phase 1 clinical trial in ten RDEB children aged 1–11 years with partial or complete 
absence of C7 in their skin. Children had skin biopsies before and after three intravenous infusions of 
bone marrow mesenchymal stromal cells (BM-MSCs) (Day 0, 7 and 28; each dose 1-3 x 106 cells/kg). 
The primary objective was to assess safety of BM-MSCs. The secondary objectives were the impact 
on disease severity and quality of life. This trial is registered, number ISRCTN46615946. Infusions 
of BM-MSCs were well tolerated with no serious adverse events. No changes in C7 expression were 
seen. Mean disease severity score decreased from baseline 28.3 to 23.1 by Day 60 (95%CI -10.7, 
0.3, p=0.06) and to 21.4 by Day 180 (-12.7, -1.1, p=0.03). Mean percentage body surface area 
affected was reduced from baseline 23.3 to 17.4 by Day 60 (-15.3, 3.5, p=0.19) and to 14.4 by Day 
180 (-18.9, 1.1, p=0.07). Median number of skin blisters reduced from 6 at baseline to 4 at Day 60 
(p=0.13) and 4 at Day 180 (p=0.79). Mean skin suction blister times increased from 613.2 seconds 
at baseline to 716.4 by Day 100 (-31.3, 237.7, p=0.12). Pain, quality of life and pruritus showed 
overall improvement. This trial identifies potential clinical benefits of intravenous BM-MSCs as a 
disease modifying intervention for children with RDEB. Further studies will need to address optimal 
cell dosage and frequency of re-treatment.    
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A novel therapeutic inhibits Rac1 mediated invasion and metastasis in a newly described in 
vivo model of human melanoma
MC Winge, J Kovalski, NT Nguyen, D Wu, A Zehnder, P Khavari and M Marinkovich 
Dermatology, Stanford Univ, Stanford, CA
Rac1, while consistently activated in human melanoma by tissue analysis, shows direct gene muta-
tional activation in only 10% of cases. From this, we hypothesized that Rac1 may play a role in 
more common BRAF and NRAS mutant driven melanomas. In this study, we overexpressed activated 
V12Rac1 mutant in primary human melanocytes (Rac1MC) and found that Rac1MC extensively 
invaded Matrigel chambers (P=0.0004) and skin equivalents in vitro. Following xenografting to SCID 
mice, Rac1MC containing skin equivalents showed extensive local invasion and systemic metastasis 
after 4 weeks (P=0.004). Through computational pathway and mRNA expression analysis of primary 
and metastatic melanoma tissue we identified NFKB as downstream of Rac1, while BRAF and NRAS 
were upstream of Rac1. Rac1MC showed altered MAPK, STAT3 and NFKB protein expression. 
NFKB-modulation through IKBα-overexpression inhibited in vitro Rac1MC invasion (P=0.0001). 
Further, Rac1 activation was detected in genetically distinct melanoma cell lines including BRAF 
V600E and NRAS Q61 mutants. Rac1-inhibitor 553502 ameliorated Matrigel invasion in BRAF 
V600E, NRAS Q61 cell lines and Rac1MC cells (P<0.003), accompanied by reduced NFKB and 
STAT3 activity. As pan-Rac1 inhibition may be toxic systemically, we assayed a repositioned drug 
(B001) we previously found modulates active Rac1, while having low toxicity in vitro and in vivo. 
Treating Rac1MCs with B001 mimicked inhibitory effects by 553502 in vitro. B001, injected IP every 
other day for four weeks dramatically inhibited in vivo invasion and metastasis of Rac1MC xeno-
grafts (P<0.05). B001 also inhibited Matrigel invasion in all melanoma cell lines assayed (P<0.05). 
Altogether, our results indicate development of a novel in vivo model of melanoma invasion and 
metastasis created by transfer of a single gene (V12Rac1) to primary human melanocytes. We also 
demonstrate Rac1 as a relevant therapeutic target across several genetically distinct melanoma 
subtypes, and introduce B001 as prototype of a novel class of agents to treat melanoma.    
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Topically delivered spherical nucleic acid nanoconjugates targeting TNF improve the pso-
riatic phenotype
K Lewandowski,1 W Daniel,2 R Kang,2 D Giljohann,2 C Mirkin3 and AS Paller1 1 
Dermatology, Northwestern University, Chicago, IL, 2 Aurasense Therapeutics, Skokie, IL and 
3 Chemistry, Northwestern University, Evanston, IL
Systemically administered tumor necrosis factor (TNF) inhibitors are highly effective for plaque pso-
riasis, but are not indicated for most patients because of their cost and associated risks. Novel spher-
ically arrayed oligonucleotide-nanoconjugates (spherical nucleic acids; SNAs) for topical delivery of 
gene suppressive therapy traverse the epidermis when delivered in a simple moisturizer, leading to 
targeted gene knockdown without observed toxicity or immune activation. We hypothesized that 
SNAs targeting human TNF could reverse the psoriatic phenotype. We engineered TNF nanocon-
jugates with antisense DNA arrayed around a central 13 nm gold nanoparticle (SNA) or a biode-
gradable liposomal nanoparticle (L-SNAs). SNAs suppressed TNF mRNA and protein expression in 
human keratinocytes (NHEKs) by 82% and 68%, respectively, in comparison with scrambled SNAs 
or PBS vehicle, while decreasing downstream S100A7 mRNA by 48% and β-DEF2A (β-defensin 
2) by 50% (all p<0.001). Knockdown with TNF L-SNAs was similar (89%; 70%; 52% and 56%, 
respectively; all p<0.001). We then engineered a 3-D model of human psoriasis by treating rafts 
6 days after lifting with 6 days of TNF, IL-17, and IL-22. Psoriasis rafts showed many morphologic 
(parakeratosis, hypogranulosis, and abnormal stratification, but no rete ridges) and transcriptomic 
(increased S100A7 and β-DEF2A; decreased keratin 10 and loricrin) changes of psoriasis. TNF or 
scrambled SNAs 50 nM or PBS were applied to the surface of psoriasis or control rafts at raft day 9 
and rafts were harvested at 12 d. SNAs targeting TNF decreased TNF mRNA by 70%, improved the 
abnormal differentiation, and reversed the psoriatic transcriptomic profile (SNA reduced S100A7 
and β-DEF2A by 53% and 56%, respectively, and L-SNA by 45% and 42%; SNAs increased keratin 
10 and loricrin by 49% and 45%, respectively, and L-SNA by 44% and 42%). SNAs and L-SNAs 
targeting TNF are a promising new topically delivered gene therapy for treating plaque psoriasis.   
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Electrophilic nitro-fatty acids suppress allergic contact dermatitis in an experimental model
AR Mathers1, 2, C Carey,1 M Killeen,1 SJ Francisco,3 B Freeman3 and LD Falo1, 4, 5 1 
Dermatology, University of Pittsburgh, Pittsburgh, PA, 2 Immunology, University of 
Pittsburgh, Pittsburgh, PA, 3 Pharmacology and Chemical Biology, University of Pittsburgh, 
Pittsburgh, PA, 4 Clinical and Translational Science Institute, University of Pittsburgh, 
Pittsburgh, PA and 5 Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA
Reactions between nitric oxide, nitrite, and unsaturated fatty acids give rise to electrophilic nitro-fatty 
acids, such as nitro-oleic acid (OA-NO2) and nitro-linoleic acid. Endogenous electrophilic fatty acids 
mediate anti-inflammatory responses by modulating metabolic and inflammatory signal transduction 
reactions. In this regard, there is considerable interest in employing electrophilic fatty acids for the 
prevention and treatment of inflammatory disorders. Our goal was to determine if OA-NO2, an 
exemplary nitro-fatty acid, has the capacity to inhibit cutaneous inflammation. Herein, we estab-
lished contact hypersensitivity as a murine preclinical model of allergic contact dermatitis (ACD) in 
Balb/c mice utilizing 1-fluoro-2,4-dinitrobenzene (DNFB) as the hapten. Additionally, subcutaneous 
(SC) OA-NO2 injections were administered 18 h prior to DNFB applications. We determined that 
SC treatments of OA-NO2 suppress ACD in both preventative and therapeutic models. In vivo SC 
OA-NO2 inhibits pathways that lead to inflammatory cell infiltration and the production of inflam-
matory cytokines (IL-1β and IL-6) in the skin. Moreover, OA-NO2 suppresses contact hypersensitivity 
by inducing both cytoprotective (HMOX-1) and immunosuppressive responses (IL-10, iNOS, Tregs). 
Overall, OA-NO2 treatments result in anti-inflammatory effects capable of resolving and inhibiting 
ACD; thus, rendering OA-NO2 as a novel medication for ACD.    
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Low dose irradiation kills malignant T cells, spares benign T cells and is a potentially curative 
therapy for mycosis fungoides
E Lowry, TR Matos, V Huang, R Watanabe, A Gehad, JE Teague, P Devlin, TS Kupper and 
R Clark Dermatology, Brigham and Women’s Hospital, DF/BWH Cancer Center, Harvard 
Medical School, Boston, MA
Mycosis fungoides (MF) is a subtype of CTCL characterized by long-standing inflammatory skin 
lesions that contain clonal malignant resident memory T cells. Although various topical therapies 
can suppress the disease, none are curative. Extremely low-dose irradiation (LDI, 4 gray x 2 treat-
ments) can lead to long-term remissions in even refractory MF. We used high throughput TCR 
sequencing (HTS) to study malignant T cells in lesional skin before and after LDI. HTS identified 
the malignant clone in 14/14 pretreatment samples. 5/5 patients who have completed therapy 
experienced complete clearing of the treated lesions. HTS demonstrated complete eradication of 
the malignant clone in 3/5 patients, and 99.8% and 81% reductions in the remaining two. Diversity 
of T cells in skin increased after therapy, numerous benign T cells remained, and tracking of T cell 
clones present prior to therapy demonstrated these cells survived LDI. In some patients, expanded 
benign T cell clones after therapy suggested LDI may encourage antitumor immunity. To study the 
differential sensitivity of malignant versus benign human T cells to LDI, we used immunodeficient 
mice grafted with human skin containing either benign resident memory T cells or the malignant 
MF T cell line MAC-1. HTS of treated grafts demonstrated that malignant T cells were markedly 
more sensitive to radiation than benign T cells. 97% of malignant T cells but only 47% of benign T 
cells were killed by 7 gray, a bioequivalent dose to the 4Gy x 2 used in patients. Benign skin T cells 
were remarkably resistant to radiation, with 30% surviving 11 gray radiation and 19% surviving 
15 gray. In summary we find that LDI effectively kills malignant T cells and spares large numbers 
of healthy skin resident T cells, cells that protect against infection and perhaps also recurrence of 
the cancer. Our results suggest low-dose irradiation may be a definitive cure for MF skin lesions 
that spares healthy immunity.    
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Regression of cutaneous squamous cell carcinomas induced by topical application of PI3K/
mTOR inhibitors
X Yang,1 C Marshall,1 T Dentchev,1 T Salah,1 S Shankar,1 F Stauffer,2 A Lerchner,2 F Seiler,2 
F Kalthoff2 and J Seykora1 1 Dermatology, Perelman School of Med, Philadelphia, PA and 2 
NIBR, Basel, Switzerland
Cutaneous squamous cell carcinoma (cSCC) is the second most common human cancer and is 
associated with activation of Erk 1/2, PI3K/mTOR, Src tyrosine kinases and JAK-STAT3. The K14-
Fyn Y528F transgenic mouse is a model of cSCC that develops pre-cancerous lesions and cSCCs 
resembling human lesions. We hypothesized that topical kinase inhibitors targeting the PI3K/mTOR 
pathway could induce regression of cSCCs in K14 Fyn Y528F mice. To test this, cohorts of K14-
Fyn Y528F mice were treated with two topical small molecule kinase inhibitors with nanomolar 
potentcy against mTOR and class I PI3K kinases. A 0.6% gel of DPT-NX7 and a 1.2% gel containing 
NIBR1112 were compared to a control gel. The DPT-NX7-treated cohort contained 25 cSCCs, the 
NIBR1112-treated cohort contained 38 cSCCs, while the control cohort contained 28 cSCCs. The 
size of cSCCs was similar in each cohort (from 8 square mm to 166 square mm) and was measured 
using calipers before treatment and weekly thereafter. The gels were applied directly to lesions 
daily. After five weeks, average tumor size decreased by about 96% in both the NIBR1112 and the 
DPT-NX7 cohorts, with a complete tumor regression rate of 79% and 76% in the NIBR1112 and 
the DPT-NX7 cohorts, respectively. No significant regression was observed in the control cohort. 
cSCC regression in both the DPT-NX7 and NIBR1112 cohorts was associated with mild epidermal 
hyperplasia, minimal inflammation and no ulceration. In contrast, topical application of 2.5% 
5-FU induced prominent ulceration and inflammation. Immuno-histochemical analysis of regressing 
cSCCs demonstrated normalization of key biomarkers such as phS6 kinase, phSTAT-3, and phPDK-
1. In summary, topical application of DPT-NX7 or NIBR1112 gel induced almost complete cSCC 
regression in the K14-Fyn Y528F model without prominent inflammation or ulceration. These data 
suggest that topical application of dual PI3K/mTOR inhibitors may be useful for treating cSCCs.   
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Etanercept for toxic epidermal necrolysis: A confirm on efficacy and safety
B Didona,1 A Paradisi,1 D Didona1, 2 and D Abeni1 1 Istituto Dermopatico dell’Immacolata-
IDI IRCCS, Rome, Italy and 2 Clinica Dermatologica, Sapienza Università di Roma, Rome, 
Italy
The aim of our study is to confirm the efficacy and safety of etanercept in toxic epidermal necrolysis. 
We observed 12 consecutive patients who were hospitalized at our Institute with toxic epidermal 
necrolysis between 2011 and 2014. We obtained written informed consent from all patients for 
treatment with etanercept. The compassionate use of etanercept for TEN had been approved by the 
Ethical Committee of our Institute. We used etenercept because this drug blocks the TNF-α and the 
lymphotoxin-α. The clinical severity of disease was computed using the SCORe of Toxic Epidermal 
Necrosis (SCORTEN) score. Using the probabilities of death linked to each level of SCORTEN score 
we calculated the expected probability of death in our patients. Healing was defined as complete 
reepithelialization. A time to healing curve was then obtained using the Kaplan–Meier product-limit 
estimates method. Nine patients had comorbidities; three patients had malignancy. The range of 
SCORTEN of our patients was between 2 and 6. In all cases, 50 mg of etanercept was administered 
in a single subcutaneous injection. All patients promptly responded to treatment, reaching complete 
reepithelialization without complications or side effects. Time to healing ranged from 7 to 20 days 
(median, 8.5 days). The upper 95% confidence interval for the 0 observed deaths (30.8%) is below 
the expected probability of death computed in our sample on the basis of patients’ SCORTEN scores 
(46.9%). Our study confirm the efficacy and safety of etanercept in toxic epidermal necrolysis and 
suggests the use of etanercept as first-line therapy for toxic epidermal necrolysis.    
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Phase I clinical trial for recessive dystrophic epidermolysis bullosa using genetically corrected 
autologous keratinocytes
Z Siprashvili,1 NT Nguyen,1 E Gorell,1 K Loutit,1 P Khuu,1 LK Furukawa,2 HP Lorenz,2 
TH Leung,1 DR Keene,3 P Khavari1, 4, A Lane,1 JY Tang1 and M Marinkovich1, 4 1 Dermatology, 
Stanford University, Stanford, CA, 2 Stanford University, Stanford, CA, 3 Shriners Hospital for 
Children, Portland, OR and 4 VA Palo Alto, Palo Alto, CA
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is an inherited genetic blistering skin disorder 
caused by mutations in the COL7A1 gene. Despite advances in the molecular diagnosis of this 
disease, current therapy is limited to supportive palliation. We have initiated the first phase I single 
center clinical trial of ex vivo gene therapy for the treatment of severe RDEB. The primary study 
objectives are expression of full-length C7 and restoration of anchoring fibrils at 3 and 6 months, as 
well as absence of RCR at 3, 6, 12 months post grafting in 5 adult RDEB subjects. The initial three 
RDEB subjects enrolled into this trial carried various heterozygous COL7A1 mutations resulting in 
expression of only truncated C7 protein undetectable by NC2 antibodies and displayed absent, or 
sparse rudimentary anchoring fibrils by EM. Autologous RDEB KC isolated from skin biopsies were 
transduced with GMP grade retrovirus carrying the full-length COL7A1. Six ~35cm2 autologous 
epidermal sheet grafts were manufactured and grafted onto prepared wound beds of each subject. 
We observed complete epidermal regeneration 30 days post grafting with clinically normal skin 
appearance at 3 and 6 months post transplantation for the first subject and 3 months post surgery for 
the second subject. The regenerated epidermis was non-pruritic and did not form blisters. Molecular 
analysis of the skin biopsies obtained from the grafted sites revealed robust C7 expression at the 
dermal-epidermal junction, detected by both NC1 and NC2 C7 antibodies, with morphologically 
normal appearance and frequency of NC2 reactive anchoring fibrils detected at the basement mem-
brane zone using EM and immuno-EM. These data indicate that genetically engineered autologous 
KC are capable of cutaneous type VII collagen delivery highlighting the potential of durable cell 
based RDEB therapy in humans.    
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Site-specific genome editing using CRISPR/Cas9 and TALENs for correction of iPS cells derived 
from dominant dystrophic epidermolysis bullosa
S Shinkuma,1 Z Guo1 and A Christiano1, 2 1 Dermatology, Columbia University, New York, 
NY and 2 Genetics and Development, Columbia University, New York, NY
Genome editing with engineered site-specific endonucleases involves non-homologous end joining 
and subsequent disruption of the open reading frame. The approach is particularly applicable to 
dominant negative disorders, which can be treated simply by knockout of the mutant allele, while 
leaving the wild type allele intact. In this study, we applied such a strategy to dominant dystro-
phic epidermolysis bullosa (DDEB) caused by a dominant negative mutation in the COL7A1 gene 
encoding type VII collagen (COL7). We performed genome editing with TALENs and CRISPR/Cas9 
targeting the mutant site-specific sequence, 8068del17insGA. DDEB-iPSC were generated from 
fibroblasts derived from a DDEB patient using episomal vectors expressing reprogramming factors. 
Then, we co-transfected Cas9 and guide RNA expression vectors expressed with GFP and DsRed, 
respectively, into DDEB-iPSC. After sorting, 90% iPSC colonies were edited and we selected four 
gene-edited iPSC lines (c.8073insA, c.8073delC, c.8072delA, and c.8072_8074delACC) for fur-
ther study. These iPSC lines were successfully differentiated into keratinocytes with retinoic acid 
and BMP4 and into fibroblasts with ascorbic acid and TGF-β. RT-PCR and western blot revealed 
gene-edited COL7 with frameshift mutations was degraded at the protein level. Our data establish 
the feasibility of site-specific genome editing to generate null alleles using CRISPR/Cas9 and TALENs 
for selective targeting of the mutation site in dominant negative disorders.    
420
Cytokine-based immunotherapy induces senescence in human melanomas
T Wieder,1 C Boss,1 E Brenner,1 H Braumüller,1 C Schulz,1 A Scheu,1 C Garbe,1 
T Feuchtinger,2 A Königsrainer3 and M Röcken1 1 Dermatology, University Tübingen, 
Tübingen, Germany, 2 General Paediatrics, University Tübingen, Tübingen, Germany and 3 
Surgery, University Tübingen, Tübingen, Germany
Recent clinical studies using immune cell-regulating antibodies demonstrated that immunotherapy 
of metastatic melanoma is effective. Besides necrosis and apoptosis, the clinical data suggest that 
the immune system activates an additional important pathway that leads to cancer control. Cellular 
senescence is a major endogenous barrier against cancer development, including BRAF-mutated 
melanoma. In this line, we showed that the combination of interferon-gamma (IFN-gamma) and 
tumor necrosis factor (TNF) induces senescence in human cancer cells in vitro. Yet, it remains 
open whether immunotherapy can induce senescence and arrest growth of human cancers also in 
vivo. We first analyzed whether the therapeutically approved IFN-alpha in combination with TNF 
can also drive melanoma cell lines or primary melanoma cells isolated from ascites patients into 
senescence. We found that some cell lines did not respond to the cytokine therapy while some 
others either showed substantial apoptosis or senescence induction. Detailed studies revealed that 
the combination of IFN-alpha and TNF induced a stable state of senescence in vitro. Senescence was 
determined by cell cycle analysis, permanent growth arrest, induction of senescence-associated-be-
ta-galactosidase (SA-beta-Gal), and senescence-defining p16Ink4a translocation. More importantly, 
intraperitoneal interferon-alpha induced extensive senescence in melanoma cells during salvage 
treatment of life-threatening, malignant ascites in two patients. Following interferon-alpha applica-
tion, intraperitoneal melanoma cells preferentially expressed the senescence marker SA-beta-Gal, 
whereas the proliferation marker Ki67 was clearly reduced. Simultaneously, melanoma cells became 
growth-arrested, expressed p16Ink4a and were cleared from the peritoneum. This is the first report 
showing that immune therapy can, besides killing, induce senescence in melanomas in vivo thereby 
critically contributing to cancer immune-control.    
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Epigenetic changes in the GPi-linked biosynthetic pathway underlie down regulation of CD52 
and resistance of CTCL patients to alemtuzumab
JE Teague,1 G Lee1, 2, A Gehad,1 E Lowry,1 DC Fisher,1 TS Kupper1 and R Clark1 1 Brigham 
and Women’s Hospital, DF/BWH Cancer Center, Harvard Medical School, Boston, MA and 
2 Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 
Seoul, Korea (the Republic of)
Alemtuzumab, an anti-CD52 antibody that depletes circulating T cells, B cells and monocytes is 
a very effective therapy for some patients with leukemic CTCL (L-CTCL). However, after treatment 
with alemtuzumab, 15/28 patients had down regulation of T cell CD52, rendering them resistant 
to further treatment. CD52 down-regulation was stable despite the absence of further alemtuzumab 
therapy and was observed in both the malignant T cells (54%) and in benign CD4 (34%) and CD8 
T cells (36%). Transcription of the CD52 gene was comparable in CD52+ and CD52- T cells and 
CD52 protein was not demonstrable in the cytoplasm. In 3/3 patients, two other GPI linked proteins 
CD55 and CD59, were also down regulated, suggesting inhibition of the GPI linkage pathway. 
Quantitative RT PCR profiling of CD52+ vs. CD52- T cells from a patient with stage IV CTCL 
demonstrated down regulation of three separate genes in the GPI biosynthetic pathway, suggesting 
epigenetic mechanisms may be at work. We screened 122 compounds with epigenetic biologic 
activity for their ability to increase CD52 expression on down regulated malignant T cells. 17/122 
compounds caused over a 100% increase in CD52 expression, although CD52 negative cells were 
still evident after one week of treatment. Of the top 17 hits, 1 targets BET, 2 target PARP, 2 target 
histone methyltransferase, 1 targets histone acetyltransferase, 1 targets HIF, 2 target aurora kinase, 
2 target DNA methyltransferase, 4 target HDAC, 1 targets JAK, 1 targets histone demethylases, and 
1 targets CDK. Ongoing studies will determine if these drugs correct the down regulated expression 
of multiple GPI biosynthetic pathway genes. In summary, we find CD52 downreguation, a serious 
clinical problem in the management of L-CTCL, may result from down regulation of multiple GPI 
pathway genes and may be addressable using medications with epigenetic activity.    
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The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in 
the ABCC6 gene: Potential treatment of PXE
Q Li,1 JP Sundberg,2 MA Levine,3 J Kingman1 and J Uitto1 1 Dermatology and Cutaneous 
Biology, Sidney Kimmel Medical College, Philadelphia, PA, 2 Research and Development, 
The Jackson Laboratory, Bar Harbor, ME and 3 Division of Endocrinology, Children’s Hospital 
of Philadelphia, Philadelphia, PA
Pseudoxanthoma elasticum (PXE) and generalized arterial calcification of infancy (GACI) are her-
itable, currently intractable, ectopic mineralization disorders. Most cases of PXE and many cases 
of GACI harbor mutations in the ABCC6 gene. There is no effective treatment for these disorders. 
In this study we explored the potential efficacy of bisphosphonates to prevent ectopic calcification 
caused by ABCC6 using Abcc6-/- mice, a model of PXE, as a preclinical platform. The mice were fed 
diet containing etidronate (ETD), 8 and 96 mg/kg/day, or alendronate (AST), 0.53 and 6.36 mg/kg/
day, corresponding to 1x and 12x of the doses used to treat osteoporosis in humans, respectively. 
The mice were placed on diet at 4 weeks of age, and the degree of mineralization was assessed at 
12 weeks by quantitation of the calcium deposits in the dermal sheath of vibrissae, an early and 
progressive biomarker of the mineralization process, by computerized morphometry of histopatho-
logic sections and by direct chemical assay of calcium. We found that ETD, but not AST, at the 
12x dosage, significantly reduced mineralization by 50-73%, however, 1x did not have any effect. 
Considering the low level of absorption of perioral ETD (<1%), subsequent studies tested the mice 
with subcutaneous injections of ETD, 0.08 and 0.96 mg/kg/day (0.01x and 0.12x). Twice weekly 
injections of ETD for 8 weeks resulted in a significant decrease in skin mineralization, as determined 
by calcium chemical assay, by 31 and 63%, respectively. These changes were accompanied by 
alterations in the trabecular bone microarchitecture, determined by μCT. The results suggest that 
selected bisphosphonates may be helpful for prevention of mineral deposits in PXE and GACI caused 
by mutations in the ABCC6 gene.    
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ONC201 induces apoptosis, inhibits proliferation, and affects cell cycle in cutaneous T-cell 
lymphoma cells
X Zhang, X Ni, T Langridge and M Duvic Department of Dermatology, The University of 
Texas MD Anderson Cancer Center, Houston, TX
Background: Cutaneous T-cell lymphomas [mycosis fungoides (MF) and Sézary Syndrome (SS)] are 
presently incurable, cause significant morbidity, and represent an unmet need for therapy. ONC201, 
a novel TRAIL-inducing compound 10 (TIC10), has potent apoptotic activity against a variety of 
solid and lymphoid tumors. In non-Hodgkin lymphoma cells, ONC201 restores TRAIL-induced 
apoptosis and exert p53-independent cytotoxicity. The purpose of this pre-clinical study was to 
evaluate mechanism of action and anti-tumor activity of ONC201 in CTCL cells. Methods: HH 
and Hut 78 (SS cells) and MJ (MF cell) and peripheral blood mononuclear cells (PBMC) from 3 
SS patients with high tumor burdens were treated with ONC201 at doses of 1~10μm for 24h to 
96h. MTS viability assay was used to measure anti-proliferation activity, apoptosis was evaluated 
with Annexin V-FITC/PI by flow cytometry, and cell-cycle distribution was also analyzed. Protein 
was evaluated by western blotting at 72h post-treatment for TRAIL, Akt, JAK3, STAT3, and NFB 
expression. Results: A dramatic anti-proliferation dose-response curve was seen in HH cells at 
2.5μm for 48h & 72h. A dose-dependent anti-proliferation response was seen in Hut78 at 72h, but 
no effect on MJ cells. A dose-response curve for apoptosis was present in HH cells at 2.5μm for 
72h, as well as in PBMCs from one SS patient. In Hut78 and PBMCs from other two SS patients, 
dose-dependent apoptosis occurred at 48h & 72h, but limited effect on MJ cells. Sub-G1 analysis 
showed apoptosis induction in MJ cells at 96h post-ONC201 in a dose-dependent manner (0.625-
10μm). TRAIL protein was induced in HH and MJ cells at 1μm, and JAK3/pJAK3 and NFB proteins 
were decreased in 3 cell lines at 1μm & 5μm at 72h post-treatment. STAT3 and Akt proteins were 
decreased in HH and Hut78 cells, but not in MJ cells. Conclusions: ONC201 as a single agent 
exerts potent anti-tumor activity on CTCL cells by inhibiting proliferation and inducing apoptosis 
in CTCL cells via down-regulation of JAK3-NFB pathways.    
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Autosomal dominant transgradient palmoplantar keratoderma (PPK) and hypotrichosis 
treated adequately with 13-cis retinoic acid and acitretin: a new phenotype of PPK with 
congenital alopecia and update on palmoplantar keratoderma-congenital alopecia syndrome
H Cohn and N Korman Dermatology, UH Case Medical Center, Cleveland, OH
Autosomal dominant palmoplantar keratoderma (PPK) with congenital alopecia (CA) has been 
described in various genodermatoses. We report a family pedigree of six individuals with hypotricho-
sis with transgradient PPK, hyperkeratotic plaques involving extensor surfaces, follicular keratotic 
papules on the ears, and half-and-half nails. The differential diagnosis includes includes Vohwinkel, 
Clouston, Hypotrichosis-osteolysis-periodontitis-PPK, KID, Olmsted and PPK-CA syndromes. The 
absence of significant hand complications, ocular, auditory, dental, and CNS abnormality narrows 
the diagnosis. Direct sequencing of the LOR coding regions yielded normal results in the proband. 
A literature review identified five familial cases of PPK with CA, with two distinct forms being 
hypothesized by Castori et al. in 2010: a benign autosomal dominant form (Stevanovic´ type), and 
a more complex autosomal recessive variant (Wallis type) with contractures, sclerodactyly, and 
pseudo-ainhum. Of the two families that have been described with Stevanovic´ type PPK-CA, one 
family revealed five members with focal, weight-bearing, non-transgradient PPK and brittle nails, 
and the other with three family members having transgradient PPK, hyperkeratotic lesions on the 
knees, elbows and perianal region and erythematous keratotic papules involving the ears with the 
additional feature of keratosis pilaris and leukonychia totalis. To our knowledge, this combination 
of transgradient PPK, extensor hyperkeratotic plaques, follicular keratotic papules on the ears, and 
half-and-half nails has not been described previously. Undoubtedly, the phenotypic variety of 
autosomal dominant PPK-CA documented by the present case suggests further studies are required 
to better understand the classification of such rare cases. Our 70-year-old patient and his daughter 
were treated long-term with retinoic acid derivatives resulting in clinical improvement in their 
transgradient PPK and hair phenotype.    
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Intrinsic resistance to smoothened inhibitors in sporadic basal cell carcinoma
P Jaju, M Rezaee, A Lee, JY Tang and K Sarin Dermatology, Stanford University, Stanford, CA
Aberrant activation of the Hedgehog (HH) signaling pathway, most commonly through loss of 
function mutations in Patched1 (PTCH) or activating mutations in Smoothened (SMO), is a cru-
cial driver of tumorigenesis in basal cell carcinoma (BCC), medulloblastoma, and other cancers. 
Smoothened inhibitors (SIs) target the HH pathway and are FDA approved for the treatment of 
advanced and metastatic BCC. Unfortunately, up to 45% of BCCs develop resistance to SIs during 
therapy. We have previously identified specific mutations in SMO that can confer SI resistance by 
disrupting drug binding or interfering with SMO autoinhibition. However, it remains unclear if these 
resistant mutations are acquired during treatment or present prior to treatment (intrinsic) in BCCs. 
We performed targeted sequencing for SMO, PTCH and TP53 in 58 sporadic untreated BCCs. 66% 
of BCCs had mutations in PTCH1, 26% in SMO, and 38% in P53. Interestingly, 9% of sporadic 
BCCs harbored SMO mutations previously shown to confer SI resistance, including SMO p.L412F 
and SMO p.W535L. Both of these mutations cause constitutive activation of SMO likely through 
releasing SMO autoinhibition. These mutations did not coexist with loss-of-function mutations 
in PTCH1, suggesting that these SMO mutations are the primary driver of tumorigenesis in these 
samples. No functionally resistant ligand binding pocket mutations were identified indicating that 
these mutations are likely acquired through mutagenesis during SI therapy. We found no correla-
tion between presence of SMO mutation and patient sex, tumor location, tumor size, p53 status or 
histology. However, functionally resistant SMO mutations were enriched in tumors acquired from 
patients 80 years and older (p<0.05). Overall, our findings suggest that at least 9% of BCCs may 
be intrinsically resistant to SMO inhibitors. Screening for mutations in SMO prior to therapy may 
allow for better stratification of patient groups more likely to respond to SIs.    
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Assessment of amlexanox, an antagonist of nonsense mediated mRNA decay (NMD), for 
the treatment of RDEB
V Atanasova, Q Jiang, J Uitto and AP South Dermatology and Cutaneous Biology, Thomas 
Jefferson University, Philadelphia, PA
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a heritable, currently intractable blistering 
disease with considerable morbidity and mortality. The disease is caused by mutations in the 
COL7A1 gene which encodes type VII collagen, the principal component of anchoring fibrils, 
structures which stabilize the adhesion between the epidermis and the dermis. Inability to form 
stable anchoring fibrils due to COL7A1 mutations results in severe skin fragility and impaired 
integrity. Nonsense mutations in the COL7A1 gene generate premature termination codons (PTCs) 
and predict truncated protein expression. PTC mutations can also lead to mRNA instability due to 
NMD, resulting in low expression of the protein. Several molecules have been shown to promote 
PTC ‘read-through’ whereby an amino acid is inserted in place of the PTC and full length protein is 
subsequently expressed. However, the ability to ‘read-through’ is limited by mRNA abundance in 
case of NMD. Therefore, inhibitors of NMD have the potential to enhance protein expression via 
PTC read-through by stabilizing the mRNA. We evaluated the efficacy of PTC read-through drugs 
in combination with NMD antagonists in immortalized keratinocytes with nonsense mutations 
cultured from RDEB patients and healthy controls. We treated cells with a number of compounds 
with read-through and NMD inhibitory potential. In particular, amlexanox, an FDA approved drug 
for the treatment of aphthous ulcers has been shown to both inhibit NMD and induce PTC ‘read-
through’ activity. We used quantitative RT-PCR to assess the level of COL7A1 mRNA relative to 
GAPDH as a result of amlexanox treatment and found that 48h incubation with 20 mM amlexanox 
led to a 2- to 7-fold increase in cell lines derived from RDEB patients relative to control non-RDEB 
keratinocytes. The efficiency of amlexanox treatment in enhancing type VII collagen expression 
in RDEB patient cells would provide the rationale for repurposing this FDA approved drug for 
immediate application in the clinical setting.    
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Differentiating endothelial cells from human induced pluripotent stem cells
Z Guo,1 C Shen,2 K Gledhill,1 HE Abaci,1 A Coffman,1 S Shinkuma,1 C Higgins,1 
B Gillette,2 SK Sia2 and A Christiano1, 3 1 Dermatology, Columbia University, New York, 
NY, 2 Biomedical Engineering, Columbia University, New York, NY and 3 Genetics and 
Development, Columbia University, New York, NY
Induced pluripotent stem cells (iPSCs) can provide an unlimited number of cells for cell therapy, 
disease modeling and drug development. Realization of the potential of iPSCs depends on the 
capacity to efficiently generate cell lineages specific for different applications. Previously published 
protocols of differentiating endothelial cells (ECs) from iPSCs often require a purification step by 
FACS or magnetic microbeads to isolate EC-like cells from a heterogeneous population containing 
cells such as pericytes, and the functionality of iPSC-derived ECs has not been widely utilized to 
construct vascularized 3D skin equivalents. Here, we aimed to improve differentiation efficiency 
of iPSCs into ECs for vascularization of 3D skin constructs. Integration-free iPSCs were generated 
from human fibroblasts by introduction of an episomal vector-based system. Endothelial cells (ECs) 
were differentiated by manipulation of the transforming growth factor β (TGF-β) signaling pathways. 
Specifically, treatment with TGF-β2 for 6 days in the presence of retinoic acid differentiated iPSCs 
into endothelial cells. Subsequent inhibition of TGF-β with SB431542 prevented the epithelial to 
mesenchymal transition, and maintained the identity of ECs. Proliferative CD31-positive endothelial 
cells (ECs) were obtained with high purity without the need for FACS or magnetic microbeads-based 
purification. These iPSC derived ECs formed vascular structures on Matrigel and in collagen gels, 
demonstrating their functionality. We have incorporated these ECs into 3D vascularized skin con-
structs to advance the application of these cells for wound healing.    
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Investigation into the safety and efficacy of human ES/iPS-derived keratinocytes for thera-
peutic reprogramming 
H Zhen, E Bashkirova, S Melo, L Li, J Torkelson, E Liaw and A Oro Dermatology, Stanford 
University School of Medicine, Stanford, CA
The advent of induced pluripotent cell (iPS) and genome editing technologies brings the possibility 
of Therapeutic Reprogramming, where genetically-corrected iPS-derived human tissues such as skin 
can be used for tissue transplantation. We have previously developed a scalable and cGMP-com-
patible protocol for Dystrophic Epidermolysis Bullosa (RDEB) patients through the generation of 
corrected human epithelial sheets and shown that they graft onto immunocompromised mice (Sebas-
tiano, Zhen et al. Sci Transl Med 2014 6: 264). However, protocol challenges and safety issues 
remain, hindering usage in patients. Here, we use GFP-tagged H9-derived human embryonic stem 
(hES) cells to improve keratinocyte manufacturing and assay the ability of undifferentiated cells to 
incorporate into skin. After induction by BMP4 and retinoic acid, we have tested several combina-
tions of media, substrates, and environments to improve uniformity of keratinocyte differentiation. 
We find that extending the culture of differentiating hES cells to 10 weeks in N2 media allows the 
formation of epithelial rosettes, uniform and highly synchronous induction of K14 and repression of 
K18 expression. These nascent epithelial sheets further expand and can be directly placed in organo-
typic culture to form stratified epithelial layers, shortening time to grafting. To assess the ability of 
undifferentiated hES cells to survive under the keratinocyte differentiating conditions, we spiked 
different ratios of ES cells into cultures or immediately prior to organotypic culture formation. We 
failed to identify surviving hES cells (detection limit of GFP or Oct4+, 1 cell in 10^5) after two weeks 
in culture or when directly added to the organotypic cultures. The hES cells also failed to incorpo-
rate into the epithelial sheet even when present in a 1:1 ratio, as they were outcompeted through 
differential adhesion. These data demonstrate improved efficacy of differentiation and provide key 
safety data in moving toward FDA approval of Therapeutic Reprogramming for RDEB patients.   
